GSK closed a deal to license two Frontier Biotechnologies siRNA assets and separately bought 35Pharma to add a pulmonary hypertension candidate, executing a two‑pronged growth push into oligonucleotide therapeutics and cardiopulmonary disease. The siRNA pact carries a modest upfront with nearly $1 billion in potential milestones; the 35Pharma acquisition brings a phase II‑ready program for pulmonary arterial hypertension. These transactions underscore big‑pharma appetite for platform buys that accelerate entry into RNA modalities and fill near‑term clinical gaps, while also illustrating how companies are using acquisitions plus licensing to diversify late‑stage portfolios.